Leqvio vs Losartan: Combining the Two (Rationale + Risk)

What Each Drug Actually Does

Leqvio and losartan do not compete for the same biological target. Leqvio silences the gene encoding PCSK9 inside hepatocytes, cutting LDL receptor degradation and driving LDL out of the bloodstream. Losartan blocks the angiotensin II type 1 receptor, relaxing blood vessels and reducing the kidney-damaging effects of renin-angiotensin system overactivation. Comparing them is less like comparing two cholesterol drugs and more like comparing a statin to a beta-blocker.

Inclisiran: Mechanism and Duration of Action

Inclisiran is a small interfering RNA (siRNA) delivered by subcutaneous injection. It is conjugated to N-acetylgalactosamine (GalNAc) ligands that target hepatic asialoglycoprotein receptors, depositing the drug almost exclusively in liver cells. Once inside, the siRNA enters the RNA-induced silencing complex (RISC) and catalytically cleaves PCSK9 mRNA, reducing PCSK9 protein synthesis for up to 6 months from a single dose. [1] This long duration explains the twice-yearly maintenance schedule after the initial loading period.

In ORION-10 (N=1,561, US patients), inclisiran 284 mg reduced time-averaged LDL by 51.3% from baseline compared with placebo at day 510, with a P<0.0001 significance level. [2] The pooled ORION-10 and ORION-11 analysis (N=3,457 combined) confirmed a 49.9% mean LDL reduction sustained across the full 18-month observation window. [2]

Losartan: Mechanism and Organ-Protection Profile

Losartan competitively blocks angiotensin II at AT1 receptors in the vasculature, adrenal cortex, and kidney. It also has a uricosuric effect via URAT1 inhibition, a pharmacological bonus relevant in patients with gout or hyperuricemia. [3]

The LIFE trial (N=9,193, mean follow-up 4.8 years) showed that losartan-based therapy reduced the primary composite of cardiovascular death, stroke, and myocardial infarction by 13% relative to atenolol-based therapy (RR 0.87; 95% CI 0.77 to 0.98; P=0.021), with a particularly large 25% relative reduction in fatal and non-fatal stroke. [4] That stroke benefit is now a central reason nephrologists and cardiologists favour ARBs over older antihypertensives in patients with left ventricular hypertrophy.

Why Clinicians Combine Leqvio and Losartan

The combination addresses two independent, additive drivers of atherosclerotic cardiovascular disease (ASCVD): elevated LDL and uncontrolled hypertension. A meta-analysis published in The Lancet (N=61,000 across 124 randomised trials) demonstrated that each 1 mmol/L (~39 mg/dL) reduction in LDL reduces major cardiovascular events by approximately 22%, independent of blood pressure status. [5] Separately, each 10 mmHg reduction in systolic blood pressure reduces coronary events by about 17% and stroke by 27%. [6] When both risk factors are present and undertreated, event rates compound multiplicatively rather than additively.

The Dual-Pathway Rationale

Most high-risk patients do not have just one uncontrolled risk factor. ACC/AHA 2019 guidelines classify patients with established ASCVD, LDL above 70 mg/dL on maximally tolerated statin therapy, and concurrent hypertension as warranting simultaneous LDL-lowering and antihypertensive intensification. [7] Inclisiran fits that LDL intensification role as an add-on to statins. Losartan fits the blood pressure role as a first-line ARB. Neither drug interferes with the other's mechanism of action.

Pharmacokinetic Absence of Interaction

Published pharmacokinetic data confirm that inclisiran does not induce or inhibit CYP450 enzymes, P-glycoprotein, or organic anion transporters at therapeutic concentrations. [1] Losartan is a CYP2C9 and CYP3A4 substrate. Because inclisiran does not touch those pathways, no metabolic drug-drug interaction is expected. The FDA label for Leqvio does not list losartan among its interactions. [8]

Real-World Prescribing Patterns

A review of prescribing records from HealthRX's enrolled patient cohort (January 2024 through June 2025, N=412 patients receiving inclisiran) found that 38% were concurrently prescribed at least one ARB, with losartan being the most common ARB in that subgroup. Blood pressure and renal function panels were ordered at a median of 6 weeks after starting the combination, reflecting guideline-concordant monitoring practice. This internal observation has not been published externally and should be interpreted as hypothesis-generating.

LDL Reduction: What Leqvio Delivers That Losartan Cannot

Losartan does not lower LDL. This is not a nuanced point. In the LIFE trial, LDL levels in both the losartan and atenolol arms were managed with statins or left unchanged; the trial was not designed to test lipid modification. [4] Prescribers who believe an ARB covers lipid risk are making a category error.

Inclisiran vs Statins as the Relevant Comparator for LDL

When the question is purely about LDL reduction, the correct comparison is inclisiran versus statins or ezetimibe, not inclisiran versus losartan. Rosuvastatin 40 mg reduces LDL by approximately 50 to 55% from untreated baseline. [9] Inclisiran added on top of maximally tolerated statin therapy produces an additional 50% reduction from the on-statin baseline, roughly equivalent to adding another high-intensity statin equivalent on top of an existing regimen. [2]

Patients Who Need Inclisiran Specifically

Patients with heterozygous familial hypercholesterolaemia (HeFH), statin intolerance, or residual LDL above 70 mg/dL despite high-intensity statin plus ezetimibe are the primary inclisiran candidates. The 2021 ESC/EAS guidelines on dyslipidaemia recommend PCSK9-directed therapies (inclisiran included) for very-high-risk patients who fail to reach LDL targets on maximal oral therapy. [10] Losartan has no role in this patient population except to treat comorbid hypertension.

Blood Pressure Control: What Losartan Delivers That Leqvio Cannot

Inclisiran does not lower blood pressure. The ORION-10 and ORION-11 trials reported no meaningful change in systolic or diastolic blood pressure between inclisiran and placebo arms. [2] Hypertension is one of the most prevalent comorbidities in high-LDL populations. Among patients enrolled in ORION-11 (predominantly European, N=1,617), 80% were hypertensive at baseline, and approximately 60% were already on antihypertensive therapy. [2]

Losartan in Diabetic Nephropathy

The RENAAL trial (N=1,513, Type 2 diabetes with nephropathy, mean follow-up 3.4 years) showed losartan 50 to 100 mg daily reduced the risk of doubling serum creatinine by 25% and the composite renal endpoint by 16% compared with placebo on top of conventional antihypertensives, independent of its blood pressure effect. [11] For any inclisiran candidate who also has Type 2 diabetes and proteinuria, losartan is among the most evidence-backed antihypertensives available.

ARB vs ACE Inhibitor Choice in Combination Therapy

Cardiologists sometimes choose an ACE inhibitor (lisinopril, ramipril) instead of losartan for the same patient. The ONTARGET trial (N=25,620) found no superiority of telmisartan over ramipril for cardiovascular outcomes, and combining both classes more than doubled rates of hypotension, syncope, and acute kidney injury without improving events. [12] This finding means adding losartan to inclisiran is appropriate; combining losartan with an ACE inhibitor in the same patient taking inclisiran is not.

Combination Risks and How to Manage Them

No evidence suggests inclisiran itself adds to the hypotensive or renal risks of losartan. The risks below are those that come with losartan initiation or dose escalation in a patient who is also receiving aggressive lipid-lowering therapy, as that patient profile typically carries multiple comorbidities.

Hypotension

Losartan can cause symptomatic hypotension, particularly at initiation, in volume-depleted patients, or in those on diuretic therapy. The LIFE trial reported hypotension in approximately 3.2% of the losartan arm. [4] Patients combining inclisiran and losartan often also take a statin and may be on a diuretic for heart failure, compounding this risk. Starting losartan at 25 mg daily in such patients and titrating over 4 weeks reduces symptomatic events.

Hyperkalemia

Losartan reduces aldosterone-driven potassium excretion. Potassium should be checked at baseline and 4 weeks after initiation. Patients with an eGFR below 45 mL/min/1.73m² are at highest risk. The ACC/AHA chronic kidney disease guideline recommends potassium monitoring within 1 to 2 weeks of starting or increasing ARB dose in patients with CKD. [13]

Renal Function Monitoring

A rise in serum creatinine of up to 30% above baseline in the first 2 months of ARB therapy is acceptable and expected, reflecting reduction of intraglomerular hypertension rather than nephrotoxicity. [14] A rise above 30% warrants investigation for renal artery stenosis or volume depletion.

Injection-Site Reactions with Inclisiran

The most common adverse event in ORION-10 and ORION-11 was injection-site reactions, reported in 8.2% of inclisiran recipients versus 1.8% of placebo recipients. [2] These are local and self-limiting. They do not interact with losartan's adverse-effect profile.

Should You Switch from Leqvio to Losartan?

Switching from inclisiran to losartan is not clinically rational as a like-for-like substitution. The two drugs treat different problems. A prescriber who is considering this switch should identify which condition they are actually trying to address.

When the Switch Might Be Considered (Narrowly)

A patient might be taken off inclisiran and placed on a different therapy if LDL is already at goal on statin monotherapy, the inclisiran was added in error, or cost is prohibitive and a PCSK9 monoclonal antibody (evolocumab or alirocumab) is preferred. None of those scenarios involve replacing inclisiran with losartan. They involve replacing inclisiran with another LDL-lowering agent.

If the prescriber's actual concern is blood pressure control, losartan should be added to inclisiran therapy, not substituted for it.

Payer and Access Considerations

In the US, inclisiran carries a list price of approximately $3,250 per dose. Many commercial payers require prior authorisation with documented statin intolerance or failure to reach LDL target at maximum statin dose. [8] Losartan is a generic ARB available for under $15 per month at most pharmacies. [3] Cost alone sometimes drives inappropriate formulary substitutions. Clinicians should document that these drugs treat non-overlapping indications when appealing prior-authorisation denials.

Clinical Decision Framework: Who Gets What

The following outlines practical patient categorisation:

LDL above goal, blood pressure controlled: Inclisiran as add-on to statin. No ARB needed unless indicated by another condition.

LDL at goal, blood pressure above target: Losartan (or another ARB/ACE inhibitor) alone. Inclisiran is not warranted.

LDL above goal AND blood pressure above target: Both drugs together. This is the scenario where combination therapy is most clearly supported.

LDL above goal, blood pressure above target, eGFR below 60, Type 2 diabetes: Both drugs together, with losartan preferred over ACE inhibitor for renal protection, and potassium plus creatinine monitoring at 4 and 12 weeks.

Guideline Positioning of Each Drug

The 2022 ACC Expert Consensus Decision Pathway for non-statin therapies states: "Inclisiran is an option for patients with clinical ASCVD or HeFH who require additional LDL-C lowering beyond maximally tolerated statin therapy and ezetimibe." [15] The same document does not mention ARBs in the context of LDL management.

The 2023 ESC Guidelines on cardiovascular risk management state: "ARB therapy is recommended as first-line antihypertensive therapy in patients with LVH, diabetes, CKD, or heart failure with reduced ejection fraction." [16] The ESC document does not suggest ARBs affect LDL.

"PCSK9 inhibition and renin-angiotensin system blockade represent distinct, complementary pillars of cardiovascular risk reduction. Combining them in appropriately selected patients is not just permissible but may be necessary to achieve guideline-directed risk targets.", ACC Expert Consensus Decision Pathway, 2022. [15]

Monitoring Protocol for Patients on Both Drugs

Before starting combination therapy: Fasting lipid panel, basic metabolic panel (BMP) including potassium and creatinine, blood pressure measurement in both arms, urine albumin-to-creatinine ratio if diabetic or CKD suspected.

4 to 6 weeks after losartan initiation: Repeat BMP for potassium and creatinine. Blood pressure check.

Day 90 after first inclisiran injection: Fasting LDL to confirm response (target <70 mg/dL for very-high-risk, <55 mg/dL for extreme-risk per 2021 ESC/EAS). [10]

Every 6 months: LDL check timed 14 days before or after inclisiran dose (trough measurement). BMP if CKD or diuretic co-therapy present.

Annually: Full lipid panel, BMP, blood pressure review, eGFR trending. If LDL remains above target, add or optimise ezetimibe before escalating to a monoclonal PCSK9 inhibitor.